Letters What happened to the polypill?

Why is there more heat than light concerning the polypill?

BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2162 (Published 20 October 2008) Cite this as: BMJ 2008;337:a2162
  1. Anthony Rodgers, professor1,
  2. Anushka Patel, director2
  1. 1School of Population Health, University of Auckland, PB92019, Auckland, New Zealand
  2. 2Cardiovascular Division, George Institute for International Health, University of Sydney, Sydney, NSW 2000, Australia
  1. a.rodgers{at}auckland.ac.nz

    Watts’s question—why are there still so few polypill trials?—is reasonable.1

    In 2001 epidemiologist Richard Peto facilitated a meeting between the World Health Organization and the Wellcome Trust to discuss development of fixed dose combination products in secondary prevention of cardiovascular disease.2 Yusuf noted the potential for a combination treatment to reduce cardiovascular risk by three quarters in the Lancet in 2002.3 …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe